癌症支持治疗多国协会（MASCC）风险指数评分作为实体瘤发热性中性粒细胞减少患者不入院标准的效用。
Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors.
作者信息
Bitar Roger A
机构信息
Consultant with Mission Infectious Disease and Infusion Consultants, Inc, in Poway, CA, and a former Infectious Disease Specialist at the San Diego Medical Center.
出版信息
Perm J. 2015 Summer;19(3):37-47. doi: 10.7812/TPP/14-188.
Abstract
Febrile neutropenic episodes in patients with solid tumors were identified electronically from 10/1/2008 to 11/15/2010. Inclusion criteria were met in 198 episodes. Sensitivity, specificity, and positive and negative predictive values of the MASCC risk index score vs complications were, respectively, 94%, 29.6%, 57.7%, and 82.9%. An MASCC risk index score of 21 or greater could not be used as a criterion for "no complication/ do not admit." Inability to eat should be an admission criterion.
摘要
2008年10月1日至2010年11月15日期间，通过电子方式识别实体瘤患者的发热性中性粒细胞减少发作情况。198次发作符合纳入标准。MASCC风险指数评分与并发症的敏感性、特异性、阳性预测值和阴性预测值分别为94%、29.6%、57.7%和82.9%。MASCC风险指数评分21分及以上不能作为“无并发症/无需住院”的标准。无法进食应作为住院标准。
相似文献
1
Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors.
Perm J. 2015 Summer;19(3):37-47. doi: 10.7812/TPP/14-188.
2
Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
Support Care Cancer. 2004 Aug;12(8):555-60. doi: 10.1007/s00520-004-0614-5. Epub 2004 Jun 9.
3
Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?
Gynecol Oncol. 2013 Sep;130(3):411-5. doi: 10.1016/j.ygyno.2013.06.018. Epub 2013 Jun 20.
4
Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Support Care Cancer. 2008 May;16(5):485-91. doi: 10.1007/s00520-007-0334-8. Epub 2007 Sep 25.
5
Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.
Support Care Cancer. 2008 Jul;16(7):841-6. doi: 10.1007/s00520-007-0347-3. Epub 2007 Oct 25.
6
Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Ann Hematol. 2008 Jul;87(7):563-9. doi: 10.1007/s00277-008-0487-7. Epub 2008 Apr 24.
7
Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
Support Care Cancer. 2018 May;26(5):1465-1470. doi: 10.1007/s00520-017-3985-0. Epub 2017 Nov 22.
8
[Prognosis prediction of febrile neutropenia by MASCC score: A retrospective study].
Bull Cancer. 2016 Jun;103(6):561-70. doi: 10.1016/j.bulcan.2016.03.008. Epub 2016 May 12.
9
Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
Ann Emerg Med. 2017 Jun;69(6):755-764. doi: 10.1016/j.annemergmed.2016.11.007. Epub 2016 Dec 29.
10
Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Indian J Cancer. 2014 Oct-Dec;51(4):491-5. doi: 10.4103/0019-509X.175340.
引用本文的文献
1
Clinical prediction models for febrile neutropenia and its outcomes: a systematic review.
Support Care Cancer. 2025 Jun 4;33(7):537. doi: 10.1007/s00520-025-09562-y.
2
Usefulness analysis of the 2018 ASCO/IDSA guideline for outpatient management of fever and neutropenia in adults treated for malignancy.
Sci Rep. 2021 Sep 15;11(1):9048. doi: 10.1038/s41598-021-88207-6.
3
Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study.
Support Care Cancer. 2021 Oct;29(10):5905-5914. doi: 10.1007/s00520-021-06154-4. Epub 2021 Mar 24.
4
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.
Cancer Biol Med. 2020 Nov 15;17(4):896-909. doi: 10.20892/j.issn.2095-3941.2020.0069. Epub 2020 Dec 15.
5
Predicting in-hospital mortality of patients with febrile neutropenia using machine learning models.
Int J Med Inform. 2020 Jul;139:104140. doi: 10.1016/j.ijmedinf.2020.104140. Epub 2020 Apr 15.
6
Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia.
PLoS One. 2019 May 23;14(5):e0216835. doi: 10.1371/journal.pone.0216835. eCollection 2019.
7
Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment?
PLoS One. 2018 Dec 31;13(12):e0210019. doi: 10.1371/journal.pone.0210019. eCollection 2018.
8
Rapid Fire: Infectious Disease Emergencies in Patients with Cancer.
Emerg Med Clin North Am. 2018 Aug;36(3):493-516. doi: 10.1016/j.emc.2018.04.001. Epub 2018 Jun 11.
9
Integrative omics to detect bacteremia in patients with febrile neutropenia.
PLoS One. 2018 May 16;13(5):e0197049. doi: 10.1371/journal.pone.0197049. eCollection 2018.
本文引用的文献
1
Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
J Clin Oncol. 2013 Feb 20;31(6):794-810. doi: 10.1200/JCO.2012.45.8661. Epub 2013 Jan 14.
2
Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients.
Br J Cancer. 2011 Aug 23;105(5):612-7. doi: 10.1038/bjc.2011.284. Epub 2011 Aug 2.
3
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.
Clin Infect Dis. 2011 Feb 15;52(4):e56-93. doi: 10.1093/cid/cir073.
4
Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.
Support Care Cancer. 2011 Oct;19(10):1625-35. doi: 10.1007/s00520-010-0993-8. Epub 2010 Sep 4.
5
Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?
Support Care Cancer. 2011 Jul;19(7):1001-8. doi: 10.1007/s00520-010-0925-7. Epub 2010 Jul 2.
6
Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.
Support Care Cancer. 2011 Aug;19(8):1151-8. doi: 10.1007/s00520-010-0928-4. Epub 2010 Jun 16.
7
Febrile neutropenia in French emergency departments: results of a prospective multicentre survey.
Crit Care. 2010;14(2):R68. doi: 10.1186/cc8972. Epub 2010 Apr 19.
8
Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Ann Hematol. 2008 Jul;87(7):563-9. doi: 10.1007/s00277-008-0487-7. Epub 2008 Apr 24.
9
Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.
J Clin Oncol. 2008 Feb 1;26(4):606-11. doi: 10.1200/JCO.2007.13.8222.
10
Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Support Care Cancer. 2008 May;16(5):485-91. doi: 10.1007/s00520-007-0334-8. Epub 2007 Sep 25.
Zotero 插件